Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Item
http://www.wikidata.org/entity/Q35784750
CCR5 monoclonal antibodies for HIV-1 therapySafety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adultsNeutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitorsMaraviroc: a review of its use in HIV infection and beyondCurrent perspectives on HIV-1 antiretroviral drug resistanceClinical significance of HIV-1 coreceptor usage.Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossV3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodiesTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryStructure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maravirocHIV-1 drug resistance and resistance testing.Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usageChemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applicationsAppreciating HIV type 1 diversity: subtype differences in Env.Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility.Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.Closing the door to human immunodeficiency virus.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.The maraviroc expanded access program - safety and efficacy data from an open-label study.Frequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing dataAnalysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West AfricaHIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02_AG isolates."Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsDistinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in ZambiaFaster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strainsVariation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsAn expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.The role of genetic variants of Stromal cell-Derived Factor 1 in pediatric HIV-1 infection and disease progression.Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.
P2860
Q22242739-10307C03-6BA5-4A83-BD01-87624F8E4E2DQ24645675-696F2808-D2B1-4FCA-BF9A-2026582CCC07Q24655129-52B0E5CD-27D1-4E92-AA54-40296C6347CBQ26778504-13480D35-1519-4858-BD50-F670A822CC86Q26852626-D19AEDB9-5B3D-49A3-BFF1-91B45D53982CQ27691426-D0FF2545-0AA9-4BFC-9243-1DC3E91B1990Q28469223-63ABD07C-7C04-457D-8C26-FF35A092C582Q28469283-EFB510DF-C077-4132-8956-097225AF05BAQ28475912-C736A739-8E79-47B1-B9A3-6321FF1B37B5Q28534396-77B20C7C-3190-4446-9D57-894F4FDAF859Q30245693-956AAEB9-6BE7-486C-A135-08CBF0A59D3FQ30278577-D0E23ADB-B3AA-4D09-92A1-99F9AE46BCAEQ30366071-B3425AB1-6E6E-4AFB-85AA-DC72CF00A9FAQ30375834-1121DA80-068D-4904-98F3-55CF427DBC50Q30376421-CB5A4122-EA1E-4624-8E37-01847DDAECC8Q30378764-FFD49477-DCA3-477A-B992-A9CAFBB2BE37Q30428089-8DC64DD0-DB4F-4033-A152-8DC7F675B289Q30654651-6522FD6A-826F-4AAA-BCC5-8E73E1B5A7DFQ30911112-17945BB8-2984-4860-B974-C9B08B40B895Q31044033-CBBEBA9E-5831-43C2-A6E7-0CCE21929247Q33597247-BA069F0C-7F29-4339-A53B-7D67AD428569Q33793066-78F1D8F9-CD8E-402F-8B70-A033D1D8BBC8Q33807529-87084573-A331-47DD-B93C-9BB021C72E56Q33810849-3CA5BABB-EA4B-4130-AB87-4C76FC7B2FE9Q33822912-A97B1F58-DB5A-4569-96D0-D01A0375ACC2Q33851789-407FF317-C867-4F2E-B387-87C40EB72F98Q33877312-8842A6C6-796E-4659-AF1D-28877FA57ED6Q33886716-6808BA38-69E1-41D6-A1B0-E5FBC0049966Q33961704-4E2E4C64-D8EE-4C5D-8198-2A3EF6AD19C7Q33990552-62267AD1-0904-40DB-A07A-14ABE1F39ABDQ34055508-4CE0DA75-2396-40DB-B650-773441D2C2ABQ34100228-17141DF8-053E-4610-BA56-E1EC35F46520Q34145972-852B6D32-269D-431D-B226-3F04A13ACCC7Q34170655-C2E8F745-D7D4-4B1E-AD4B-4CC1D358D609Q34280466-304E1F11-57B6-42FE-8752-21213FB6D9FBQ34351378-AC6F9FA0-B780-401A-BFFE-D8198C8582C1Q34409877-D41AFA2F-ECA3-424D-BDA5-10517AAAAF38Q34437126-4E51BB1A-88DA-4060-946D-A46CE0BB3751Q34489239-15B26516-EEE9-417B-A6F7-2A457E2766AEQ34565057-D4A12A60-F42E-49FA-99F1-A8A13EA15B30
P2860

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Item
http://www.wikidata.org/entity/Q35784750
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@ast
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@en
type
label
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@ast
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@en
prefLabel
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@ast
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Reduced maximal inhibition in ...... itor-bound receptor for entry.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932